Answers are grounded in this paper and cite their sources.
Importance: Patients are increasingly learning Alzheimer disease (AD) genetic and biomarker results through electronic health portals. Evaluation of alternative scalable delivery models for return of AD risk information is needed to best support patient knowledge and psychological well-being. Objective: To determine whether a digital platform is comparable to clinician-mediated telehealth sessions for returning apolipoprotein E (APOE) genotype and plasma phosphorylated tau 217 (p-tau217) results on outcomes of knowledge and psychological well-being. Design, Setting, and Participants: The Evaluation of Self-Mediated Alternatives for Risk Testing Education and Return of Results (eSMARTER) study was a noninferiority trial of a digital platform compared to clinician-mediated return of APOE genotype and optional p-tau217 results. Enrollment was conducted October 2024 through February 2025. Follow-up was completed November 2025. This was a decentralized, fully remote trial taking place across the contiguous US. Eligible participants were aged 60 to 80 years and had previously undergone APOE genotyping (without disclosure) via GeneMatch, passed psychological screening, had internet access, and could speak English. Of the 13 033 people invited by GeneMatch, 2052 accepted, and 813 were assessed for eligibility. Of 666 randomized, 651 were ultimately included. Interventions: Participants were randomized, 2:1, to the eSMARTER digital platform or study clinician-mediated return of APOE genotype. Following the 6-month post-APOE assessment, participants were offered optional p-tau217 disclosure via the same randomized modality. Main Outcomes and Measures: Primary outcomes at 1 to 7 days following APOE disclosure included changes in anxiety, disease-specific distress, and AD-related knowledge within a priori noninferiority margins. Results: A total of 674 persons were eligible and provided demographic information. Of these, 651 participants had been randomized to study clinician-mediated (n = 216) or digital disclosure (n = 435) and completed APOE disclosure (mean [SD] age, 68 [4.7] years; 439 [67%] female; mean [SD] telephone Montreal Cognitive Assessment score, 19 [2]; 66 [10%] APOE4 homozygotes, 377 [58%] heterozygotes, and 208 [32%] noncarriers) A total of 604 participants completed the study; 500 completed optional p-tau217 disclosure. Baseline characteristics were balanced across groups. At 1 to 7 days following APOE disclosure, scores on AD-related knowledge, Patient-Reported Outcomes Measurement Information System Anxiety T-score, and disease-specific distress measures met noninferiority. Conclusions and Relevance: Return of APOE genotype by the eSMARTER digital platform is noninferior to study clinician-mediated telehealth disclosure. No significant between-group differences were found following return of p-tau217 results. Together, these results suggest that this digital platform may provide an evidence-based scalable approach for returning AD genetic and biomarker results. Trial Registration: ClinicalTrials.gov Identifier: NCT06459583.
No takes yet. Share an insight, caveat, or question.
Langbaum et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: